Probiotic Supplementation for Treatment of Helicobacter pylori Infection: A Double-Blind Randomized Clinical Trial

Background/Aims: The effects of probiotic supplementation on <i>Helicobacter pylori (H. pylori)</i> eradication therapy are not completely understood. In this study, we investigated the continuous administration rates, recrudescence, and symptom response following completion a course <i>H. pylori</i> therapy.Methods: This prospective, randomized, double-blind placebo-controlled trial was performed between June 2018 2020. Twohundred seventy patients who received standard triple regimen for eradication, were included in study. Participants randomized to receive as adjunctive (<i>Enterococcus faecium</i> 4.5×10<sup>8</sup> Bacillus subtilis 5.0×10<sup>7</sup>; Medilac-S®, Hanmi Pharmaceuticals, Seoul, Korea) or placebo (one tablet thrice daily) 28 days, eradication. showed successful underwent repeat <sup>13</sup>C-urea breath test after 6 months.Results: Eradication rates groups 77.1% 72.4%, respectively (<i>P</i>=0.48) using per-protocol analysis. Using intention-to-treat analysis, 67.4% 65.9%, (<i>P</i>=0.43). Of 149 followed-up months, four had recrudescence (2.7%). Recrudescence did differ groups. 76 non-ulcer dyspepsia, 60 (78.9%) resolution months. beneficial effect most pronounced with postprandial distress syndrome (<i>P</i>=0.02).Conclusions: Consecutive increase decrease rates.